Skip to main content
SpringerLink
Log in

Integrative Therapies for People with Cystic Fibrosis

  • Chapter
  • First Online:
Book cover Integrative Therapies in Lung Health and Sleep

Part of the book series: Respiratory Medicine ((RM,volume 4))

Abstract

Cystic fibrosis (CF) is the most common lethal autosomal inherited disorder affecting Caucasian populations. Due to improved treatments and multidisciplinary team care, the life expectancy of patients with CF has increased dramatically in the last 2 decades. Medical therapy for the majority of patients consists of regular sputum clearance, mucolytic therapy, antibiotics, pancreatic enzyme replacement, nutritional support, and anti-inflammatory agents such as azithromycin. Review by complementary and alternative medicine (CAM) therapists and the utilization of CAM medicines is common in people with CF and healthcare practitioners should encourage discussion with their patients about the use of such therapies. Data to date on the effectiveness of CAM therapy in CF are limited; therefore, adequately powered and carefully designed studies are required to enhance knowledge of the correct role of such therapies. Collaborations between academic centers established to evaluate CAM therapies with CF researchers would provide excellent opportunity to enhance the study of the role of CAM.

* Conflict of Interest Statement: Neither author has a financial or other interest in any of the products discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cystic Fibrosis Foundation Patient Registry. 2009 Annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2009.

    Google Scholar 

  2. De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax. 2006;61:627–35.

    Article  PubMed  Google Scholar 

  3. Anon. Cystic Fibrosis Foundation Patient Registry. 2009 Annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2009.

    Google Scholar 

  4. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891–904.

    Article  PubMed  Google Scholar 

  5. Cystic Fibrosis Foundation. 2010 Annual Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2010.

    Google Scholar 

  6. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125 Suppl 1:1S–39.

    Article  PubMed  Google Scholar 

  7. Christie JD, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transpl. 2010;29(10):1104–18.

    Article  Google Scholar 

  8. Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ. 1998;316(7147):1771–5.

    Article  PubMed  CAS  Google Scholar 

  9. Johnston C, Butler SM, Konstan MW, Morgan W, Wohl ME. Factors influencing outcomes in cystic fibrosis: a centre-based analysis. Chest. 2003;123:20–7.

    Article  Google Scholar 

  10. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991–2003.

    Article  PubMed  CAS  Google Scholar 

  11. http://www.vrtx.com/current-projects/drug-candidates/VX-809.html. 2011. Accessed 06/07/2011, 2011.

  12. Pryor JA, Tannenbaum E, Scott SF, et al. Beyond postural drainage and percussion: airway clearance in people with cystic fibrosis. J Cyst Fibros. 2010;9:187–92.

    Article  PubMed  CAS  Google Scholar 

  13. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241–50.

    Article  PubMed  CAS  Google Scholar 

  14. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229–40.

    Article  PubMed  CAS  Google Scholar 

  15. Fuchs HJ, Borowitz DS, Christiansen DH, Group TPS, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331:637–42.

    Article  PubMed  CAS  Google Scholar 

  16. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;332:848–54.

    Article  PubMed  CAS  Google Scholar 

  17. Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr. 2007;151:249–54.

    Article  PubMed  CAS  Google Scholar 

  18. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749–56.

    Article  PubMed  CAS  Google Scholar 

  19. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57(3):212–6.

    Article  PubMed  CAS  Google Scholar 

  20. Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med. 2006;173(12):1356–62.

    Article  PubMed  CAS  Google Scholar 

  21. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990;141:914–21.

    PubMed  CAS  Google Scholar 

  22. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20:658–66.

    Article  PubMed  CAS  Google Scholar 

  23. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010;45(11):1121–34.

    Article  PubMed  Google Scholar 

  24. Ramsey BW, Pepe MS, Quan JM, et al. Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23–30.

    Article  PubMed  CAS  Google Scholar 

  25. Borowitz D, Baker R, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:246–59.

    Article  PubMed  Google Scholar 

  26. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 1998;280(18):1569–75.

    Article  PubMed  CAS  Google Scholar 

  27. What is complementary and alternative medicine (CAM)? National Center for Complementary and Alternative Medicine [online] 2004; http://nccam.nih.gov/health/whatiscam.

  28. Stern RC, Canda ER, Doershuk CF. Use of nonmedical treatment by cystic fibrosis patients. J Adolesc Health. 1992;13(7):612–5.

    Article  PubMed  CAS  Google Scholar 

  29. Tanase A, Zanni R. The use of complementary and alternative medicine among pediatric cystic fibrosis patients. J Altern Complement Med. 2008;14(10):1271–3.

    Article  PubMed  Google Scholar 

  30. Samdup DZ, Smith RG, Il Song S. The use of complementary and alternative medicine in children with chronic medical conditions Am J Phys Med Rehabil. 2006;85(10):842–6.

    Google Scholar 

  31. Burrows JA, Bajramovic J, Bell SC. Prevalence of complementary and alternative medicine use by adults with cystic fibrosis. J Pharm Pract Res. 2002;32(4):320–3.

    Google Scholar 

  32. Chung Y, Dumont RC. Complementary and alternative therapies: use in pediatric pulmonary medicine. Pediatr Pulmonol. 2011;46(6):530–44.

    Article  PubMed  Google Scholar 

  33. Ravilly S, Robinson W, Suresh S, Wohl M, Berde C. Chronic pain in cystic fibrosis. Pediatrics. 1996;98(4):741–7.

    PubMed  CAS  Google Scholar 

  34. Festini F, Ballarin S, Codamo T, Doro R, Laganes C. Prevalence of pain in adults with cystic fibrosis. J Cyst Fibros. 2004;3:51–7.

    Article  PubMed  Google Scholar 

  35. Hernandez-Reif M, Field T, Krasnegor J, Martinez E, Schwartzman M, Mavunda K. Children with cystic fibrosis benefit from massage therapy. J Pediatr Psychol. 1999;24(2):175–81.

    Article  PubMed  CAS  Google Scholar 

  36. Lee A, Holdsworth M, Holland A, Button B. The immediate effect of musculoskeletal physiotherapy techniques and massage on pain and ease of breathing in adults with cystic fibrosis. J Cyst Fibros. 2009;8(1):79–81.

    Article  PubMed  Google Scholar 

  37. Coulter ID, Hurwitz EL, Adams AH, Genovese BJ, Hays R, Shekelle PG. Patients using chiropractors in North America: who are they, and why are they in chiropractic care? Spine. 2002;27:291–6.

    Article  PubMed  Google Scholar 

  38. Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int. 2010;86:1–7.

    Article  PubMed  CAS  Google Scholar 

  39. White A. A cumulative review of the range and incidence of significant adverse events associated with acupuncture. Acupunct Med. 2004;22:122–33.

    Article  PubMed  Google Scholar 

  40. Lin YC, Ly H, Golianu B. Acupuncture pain management for patients with cystic fibrosis: a pilot study. Am J Chin Med. 2005;33(1):151–6.

    Article  PubMed  Google Scholar 

  41. Scott E. Acupuncture for the relief of pain in cystic fibrosis. Cystic Fibrosis Worldwide Newsletter. 22 May 2011. p. 11.

    Google Scholar 

  42. Rustøen T, Wahl AK, Hanestad BR, Gjengedal E, Moum T. Expressions of hope in cystic fibrosis patients: a comparison with the general population. Heart Lung. 2004;33:111–8.

    Article  PubMed  Google Scholar 

  43. Pfeffer PE, Pfeffer JM, Hodson ME. The psychosocial and psychiatric side of cystic fibrosis in adolescents and adults. J Cyst Fibros. 2003;2:61–8.

    Article  PubMed  CAS  Google Scholar 

  44. Goldbeck L, Besier T, Hinz A, Singer S, Quittner AL, Group T. Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis. Chest. 2010;138(4):929–36.

    Article  PubMed  Google Scholar 

  45. Szyndler JE, Towns SJ, van Asperen PP, McKay KO. Psychological and family functioning and quality of life in adolescents with cystic fibrosis. J Cyst Fibros. 2005;4:125–44.

    Article  Google Scholar 

  46. Napolitano MA, Babyak MA, Palmer S, et al. Effects of a telephone-based psychosocial intervention for patients awaiting lung transplantation. Chest. 2002;122:1176–84.

    Article  PubMed  Google Scholar 

  47. Delk KK, Gevirtz R, Hicks DA, Carden F, Rucker R. The effects of biofeedback assisted breathing retraining on lung functions in patients with cystic fibrosis. Chest. 1994;105:23–8.

    Article  PubMed  CAS  Google Scholar 

  48. Glasscoe CA, Quittner AL. Psychological interventions for people with cystic fibrosis and their families. Cochrane Database Syst Rev. 2008;16(3):CD003148.

    Google Scholar 

  49. Belsky J, Khanna P. The effects of self-hypnosis for children with cystic fibrosis: a pilot study. Am J Clin Hypn. 1994;36:282–92.

    Article  PubMed  CAS  Google Scholar 

  50. Anbar RD. Self-hypnosis for patients with cystic fibrosis. Pediatr Pulmonol. 2000;30:461–5.

    Article  PubMed  CAS  Google Scholar 

  51. Grasso M, Button BM, Allison DJ, Sawyer SM. Benefits of music therapy as an adjunct to chest physiotherapy in infants and toddlers with cystic fibrosis. Pediatr Pulmonol. 2000;29:371–81.

    Article  PubMed  CAS  Google Scholar 

  52. Wiens ME, Reimer MA, Guyn HL. Music therapy as a treatment method for improving respiratory muscle strength in patients with advanced multiple sclerosis. A pilot study. Rehabil Nurs. 1999;24(2):74–80.

    PubMed  CAS  Google Scholar 

  53. Collyer S, Kenny DT, Archer M. The effect of abdominal directives on breathing patterns in female classical singing. Logoped Phoniatr Vocol. 2009;34(3):100–10.

    Article  PubMed  Google Scholar 

  54. Irons JY, Kenny DT, Chang AB. Singing for children and adults with cystic fibrosis. Cochrane Database Syst Rev. 2010;12(5):CD008036.

    Google Scholar 

  55. Hurley MN, Forrester DL, Smyth AR. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database Syst Rev. 2010;6(10):CD008037.

    Google Scholar 

  56. Cheng K, Smyth RL, Govan JRW, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348:639–42.

    Article  PubMed  CAS  Google Scholar 

  57. Alhede M, Bjarnsholt T, Jensen PØ, et al. Pseudomonas aeruginosa recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. Microbiology. 2009;155(Pt 11):3500–8.

    Article  PubMed  CAS  Google Scholar 

  58. Rasmussen TB, Bjarnsholt T, Skindersoe ME, et al. Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector. J Bacteriol. 2005;187:1799–814.

    Article  PubMed  CAS  Google Scholar 

  59. Bjarnsholt T, Jensen PO, Rasmussen TB, et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology. 2005;151:3873–80.

    Article  PubMed  CAS  Google Scholar 

  60. Hurley MN, Crusz SA, Symonds ME, et al. A commercial garlic preparation exerts global inhibition of the quorum sensing (QS) system and virulence factor production of laboratory and clinical strains of Pseudomomas aeruginosa. J Cyst Fibros. 2011;10 Suppl 1:S24.

    Article  Google Scholar 

  61. Smyth AR, Cifelli PM, Ortori CA, et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis—a pilot randomized controlled trial. Pediatr Pulmonol. 2010;45(4):356–62.

    PubMed  Google Scholar 

  62. O’Hara M, Kiefer D, Farrell K, Kemper K. A review of 12 commonly used medicinal herbs. Arch Fam Med. 1998;7:523–36.

    Article  PubMed  Google Scholar 

  63. Song Z, Johansen HK, Faber V, et al. Ginseng treatment reduces bacterial load and lung pathology in chronic Pseudomonas aeruginosa pneumonia in rats. Antimicrob Agents Chemother. 1997;41:961–4.

    PubMed  CAS  Google Scholar 

  64. Song Z, Kharazmi A, Wu H, Johansen HK, Faber V, Høiby N. Immunomodulatory properties of ginseng—effects on Pseudomonas aeruginosa lung infection. Clin Microbiol Infect. 1999;5:S37–8.

    Google Scholar 

  65. Song Z, Konga KF, Wub H, et al. Panax ginseng has anti-infective activity against opportunistic pathogen Pseudomonas aeruginosa by inhibiting quorum sensing, a bacterial communication process critical for establishing infection. Phytomedicine. 2010;17:1040–6.

    Article  PubMed  CAS  Google Scholar 

  66. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004;304(5670):600–2.

    Article  PubMed  CAS  Google Scholar 

  67. Wang W, Bernard K, Li G, Kirk KL. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem. 2007;16:4533–44.

    Google Scholar 

  68. Harada K, Okiyoneda T, Hashimoto Y, et al. Curcumin enhances cystic fibrosis transmembrane regulator expression by down-regulating calreticulin. Biochem Biophys Res Commun. 2007;353:351–6.

    Article  PubMed  CAS  Google Scholar 

  69. Song Y, Sonawane ND, Salinas D, et al. Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem. 2004;279(39):40629–33.

    Article  PubMed  CAS  Google Scholar 

  70. Yu YC, Miki H, Nakamura Y, et al. Curcumin and genistein additively potentiate G551D-CFTR. J Cyst Fibros. 2011;10(4):243–52.

    Article  PubMed  CAS  Google Scholar 

  71. Brown RK, Wyatt H, Price JF, Kelly FJ. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur Respir J. 1996;9(2):334–9.

    Article  PubMed  CAS  Google Scholar 

  72. Back EI, Frindt C, Nohr D, et al. Antioxidant deficiency in cystic fibrosis: when is the right time to take action? Am J Clin Nutr. 2004;80(2):374–84.

    PubMed  CAS  Google Scholar 

  73. Lancellotti L, D’Orazio C, Mastella G, Mazzi G, Lippi U. Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation. Eur J Pediatr. 1996;155:281–5.

    Article  PubMed  CAS  Google Scholar 

  74. Shamseer L, Adams D, Brown N, Johnson JA, Vohra S. Antioxidant micronutrients for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2010;12:CD007020.

    PubMed  Google Scholar 

  75. Olveira G, Olveira C, Acosta E, et al. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Arch Bronconeumol. 2010;46:70–7.

    Article  PubMed  Google Scholar 

  76. McKarney C, Everard M, N’Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst Rev. 2007;17:CD002201.

    Google Scholar 

  77. Bruzzese E, Raia V, Spagnuolo MI, et al. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr. 2007;26:322–8.

    Article  PubMed  Google Scholar 

  78. Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther. 2004;20:813–9.

    Article  PubMed  CAS  Google Scholar 

  79. Weiss B, Bujanover Y, Yahav Y, Vilozni D, Fireman E, Efrati O. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol. 2010;45:536–40.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Medicine, The Prince Charles Hospital, Rode Road, Chermside Brisbane, QLD, 4032, Australia

    Claire A. Butler MB, BCh, BAO, MRCP & Scott C. Bell MBBS, MD, FRACP

Authors
  1. Claire A. Butler MB, BCh, BAO, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott C. Bell MBBS, MD, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott C. Bell MBBS, MD, FRACP .

Editor information

Editors and Affiliations

  1. , School of Nursing, University of Minnesota, 308 Harvard St. SE, Minneapolis, 55455, Minnesota, USA

    Linda Chlan

  2. , Department of Pulmonary, Allergy, and Cr, University of Minnesota, 401 East River Road, Minneapolis, 55455, Minnesota, USA

    Marshall I. Hertz

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Butler, C.A., Bell, S.C. (2012). Integrative Therapies for People with Cystic Fibrosis. In: Chlan, L., Hertz, M. (eds) Integrative Therapies in Lung Health and Sleep. Respiratory Medicine, vol 4. Humana Press. https://doi.org/10.1007/978-1-61779-579-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-579-4_6

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-578-7

  • Online ISBN: 978-1-61779-579-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation